Cite
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
MLA
Hortobagyi, Gabriel N., et al. “Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.” New England Journal of Medicine, vol. 386, no. 10, Mar. 2022, pp. 942–50. EBSCOhost, https://doi.org/10.1056/NEJMoa2114663.
APA
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Hart, L., Campone, M., Petrakova, K., Winer, E. P., Janni, W., Conte, P., Cameron, D. A., André, F., Arteaga, C. L., Zarate, J. p., Chakravartty, A., Taran, T., Le Gac, F., Serra, P., & O’Shaughnessy, J. (2022). Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. New England Journal of Medicine, 386(10), 942–950. https://doi.org/10.1056/NEJMoa2114663
Chicago
Hortobagyi, Gabriel N., Salomon M. Stemmer, Howard A. Burris, Yoon-Sim Yap, Gabe S. Sonke, Lowell Hart, Mario Campone, et al. 2022. “Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.” New England Journal of Medicine 386 (10): 942–50. doi:10.1056/NEJMoa2114663.